Evidence map›Paper›PMID 37875656›Full record

ReviewOncogene2023

Translation of tissue-based artificial intelligence into clinical practice: from discovery to adoption.

Alice Geaney, Paul O'Reilly, Perry Maxwell, Jacqueline A James, Darragh McArt, Manuel Salto-Tellez

Abstract readReview
In one paragraph

Review in Oncogene, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Alice Geaney *Sonraí Analytics, Whitla Medical Building, 97 Lisburn Rd, Belfast, BT9 7BL, UK.
Paul O'Reilly *Sonraí Analytics, Whitla Medical Building, 97 Lisburn Rd, Belfast, BT9 7BL, UK.
Perry Maxwell *Precision Medicine Centre of Excellence, The Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Health Science Building; 97 Lisburn Road, Belfast, BT9 7BL, UK.
Jacqueline A James *Precision Medicine Centre of Excellence, The Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Health Science Building; 97 Lisburn Road, Belfast, BT9 7BL, UK.ORCID 0000-0002-6945-6060
Darragh McArt *Sonraí Analytics, Whitla Medical Building, 97 Lisburn Rd, Belfast, BT9 7BL, UK.
Manuel Salto-Tellez *Precision Medicine Centre of Excellence, The Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Health Science Building; 97 Lisburn Road, Belfast, BT9 7BL, UK. manuel.salto-tellez@icr.ac.uk.ORCID 0000-0001-8586-282X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Digital pathology (DP), or the digitization of pathology images, has transformed oncology research and cancer diagnostics. The application of artificial intelligence (AI) and other forms of machine learning (ML) to these images allows for better interpretation of morphology, improved quantitation of biomarkers, introduction of novel concepts to discovery and diagnostics (such as spatial distribution of cellular elements), and the promise of a new paradigm of cancer biomarkers. The application of AI to tissue analysis can take several conceptual approaches, within the domains of language modelling and image analysis, such as Deep Learning Convolutional Neural Networks, Multiple Instance Learning approaches, or the modelling of risk scores and their application to ML. The use of different approaches solves different problems within pathology workflows, including assistive applications for the detection and grading of tumours, quantification of biomarkers, and the delivery of established and new image-based biomarkers for treatment prediction and prognostic purposes. All these AI formats, applied to digital tissue images, are also beginning to transform our approach to clinical trials. In parallel, the novelty of DP/AI devices and the related computational science pipeline introduces new requirements for manufacturers to build into their design, development, regulatory and post-market processes, which may need to be taken into account when using AI applied to tissues in cancer discovery. Finally, DP/AI represents challenge to the way we accredit new diagnostic tools with clinical applicability, the understanding of which will allow cancer patients to have access to a new generation of complex biomarkers.

Indexed as

Artificial IntelligenceNeoplasmsBiomarkers, TumorHumansMachine LearningMedical OncologyBiomarkers, Tumor

Identifiers

PMID37875656
PMCPMC10673711

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.